Barr Prozac Appeal Claims Lilly Double Patenting; Seeks Patent Invalidation
Executive Summary
Barr is focusing its appellate challenge of the Prozac patent ruling on double patent claims.
You may also be interested in...
Bristol's Taxol Appeal Emphasizes Contribution Of Improved Dosing Regimen
Bristol-Myers Squibb's Taxol patent appeal hinges in part on the company's arguments that it should receive a reward for bringing an improved dosing schedule for paclitaxel to the public.
Bristol's Taxol Appeal Emphasizes Contribution Of Improved Dosing Regimen
Bristol-Myers Squibb's Taxol patent appeal hinges in part on the company's arguments that it should receive a reward for bringing an improved dosing schedule for paclitaxel to the public.
Lilly, Barr Expect Prozac Generics In August 2001 After Appeals Court Ruling
Lilly and Barr expect generic competition to Prozac to arrive in August 2001 after an Aug. 9 Washington D.C. federal appeals court decision in favor of Barr's challenge of a fluoxetine patent.